Industry News

Pharmaceutical Industry News

By nailing the primary endpoint in…

September 8th, 2025|Fierce Pharma|

By nailing the primary endpoint in a phase 3 trial, Eli Lilly's Bruton tyrosine kinase (BTK) inhibitor Jaypirca has come one step closer to reaching a broader group of patients with blood cancer.

Industry watchers who cheered on…

September 6th, 2025|Fierce Pharma|

Industry watchers who cheered on Summit Therapeutics’ claim that the first global phase 3 trial of its Akeso-partnered PD-1xVEGF drug showed consistent benefit between China and Western populations may be disappointed, although hopes for an

Five months after embarking on a…

September 5th, 2025|Fierce Pharma|

Five months after embarking on a “massive testing and research effort” to root out the cause of the nation's "autism epidemic," Robert F. Kennedy Jr. is getting ready to present his findings this month.

Spending on point-of-care drug…

September 5th, 2025|Fierce Pharma|

Spending on point-of-care drug marketing is on the rise. The revenues of members of the Point of Care Marketing Association climbed 16% last year to break the $1 billion barrier.

More than 200 employees at…

September 5th, 2025|Fierce Pharma|

More than 200 employees at Perrigo's Bronx plant have been on strike since Sept. 2 as the company looks to expand its operations at the site to seven days a week, according to a local

The “Pledge to Champion a…

September 5th, 2025|Fierce Pharma|

The “Pledge to Champion a Menopause-Inclusive Workplace” initially began last fall as an internal initiative, but Astellas is now rolling it out worldwide for other businesses to join, with the external launch tied to Menopause

In a familiar refrain, the…

September 5th, 2025|Fierce Pharma|

In a familiar refrain, the European Medicines Agency is warning consumers about a 'sharp rise' in the illegitimate sale of counterfeit versions of Eli Lilly's and Novo Nordisk's diabetes and weight loss drugs.

In an amended complaint filed…

September 5th, 2025|Fierce Pharma|

In an amended complaint filed Thursday in Delaware federal court, GSK’s legal team said the company will also seek royalties on mNexspike after leveling initial patent infringement claims against Moderna’s first COVID vaccine, Spikevax, and

AstraZeneca’s Tagrisso-chemo…

September 5th, 2025|Fierce Pharma|

AstraZeneca's Tagrisso-chemo regimen significantly reduced the risk of death by 23% compared with Tagrisso alone in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer, an updated analysis of the phase 3 Flaura2 trial

Hope, when applied with purpose…

September 5th, 2025|Fierce Pharma|

Hope, when applied with purpose and action, can be a powerful force for driving change. In this episode of "The Top Line," Advocate Health CEO and Fierce 50 honoree Eugene Woods draws on more than

It was déjà vu all over again…

September 4th, 2025|Fierce Pharma|

It was déjà vu all over again for TV drug ad spending in August, as the top 10 spenders barely deviated from July’s list and turned in a combined total nearly identical to the preceding

PatientPartner transforms pharma…

September 4th, 2025|Fierce Pharma|

PatientPartner transforms pharma brands' patient marketing and engagement efforts with the launch of the “PerfectPatient”, an AI-powered mentor that personalizes every patient’s journey.

During a tense and at times…

September 4th, 2025|Fierce Pharma|

During a tense and at times incendiary Senate hearing Thursday, Robert F. Kennedy Jr. blamed the pharmaceutical industry and fell back on vaccine misinformation as he sought to defend the tumult that has consumed the